Freddie Mac Jun 2004 - Mar 2011
Risk Manager
Wells Fargo Jun 2004 - Mar 2011
Risk Cons
Juniper Financial May 2001 - Jun 2003
Fraud Risk Mananger
First Usa Sep 1999 - May 2001
Financial Analyst
Education:
Penn State University 1997 - 1999
Master of Science, Masters
Lousiana State University 1991 - 1993
Masters, Master of Arts, Education
Peking University 1985 - 1991
The Office of James Burnett - San Diego since Aug 2011
Associate
AECOM Jun 2010 - Aug 2010
Intern as assistant landscape architect
Beijing Forestry University Sep 2004 - Jul 2008
BLA Student
Education:
Department of Landscape Architecture & Regional Planning, University of Massachusetts Amherst 2009 - 2011
Master, Landscape Architecture
School of Landscape architecture, Beijing Forestry University 2004 - 2008
Bachelor, Landscape Architecture
Skills:
AutoCAD Photoshop ArcGIS Rendering InDesign PowerPoint Illustrator Microsoft Word Microsoft Excel Chinese Public Speaking Modeling Programming
Second Price of the 5th Ed Bacon Student Competition - Ed Bacon Foundation 2010 (http://www.edbacon.org/usa250/winners.htm)
Third Price of Student Competition - IFLA APR 2009
Medicine Doctors
Dr. Xiao M Zhou, Rockville MD - MD (Doctor of Medicine)
The invention relates to methods and compositions of WW-domains as phosphoserine and phosphothreonine binding modules. The WW-domain containing polypeptides of the invention can be used, for example, to regulate cell growth; to treat neurodegenerative diseases; to screen for substances that modulated interactions between WW-domain containing polypeptides and phosphorylated ligands; as drug targeting vehicles; to direct protein degradation; and in the treatment of certain diseases or conditions characterized by aberrant WW-domain containing polypeptides or their ligands.
Kun Ping Lu - Newton MA, US Xiao Zhen Zhou - Newton MA, US Gerburg Wulf - Cambridge MA, US
Assignee:
Beth Israel Deaconess Medical Center - Boston MA
International Classification:
G01N 33/53
US Classification:
435 723
Abstract:
Methods for the use of Pin1 as a marker of abnormal cell growth are disclosed. In one embodiment, the method includes detecting a level of Pin1 to stage an abnormal cell growth, such as breast or prostate cancer. In another embodiment, the method includes evaluating the efficacy of a treatment of an abnormal cell growth, such as cancer, by monitoring the levels of Pin1. In another embodiment, the method includes evaluating the extent of metastasis of abnormal cell growth, such as cancer. The levels of Pin1 can be protein levels or nucleic acid levels.
Kun Lu - Newton MA, US Gerburg Wulf - Cambridge MA, US Xiao Zhou - Newton MA, US
International Classification:
C12Q001/68 G01N033/574
US Classification:
435/006000, 435/007230
Abstract:
Methods for the use of Pin1 as a marker of abnormal cell growth are disclosed. In one embodiment, the method includes detecting a level of Pin1 to stage an abnormal cell growth, such as breast or prostate cancer. In another embodiment, the method includes evaluating the efficacy of a treatment of an abnormal cell growth, such as cancer, by monitoring the levels of Pin1. In another embodiment, the method includes evaluating the extent of metastasis of abnormal cell growth, such as cancer. The levels of Pin1 can be protein levels or nucleic acid levels.
Methods And Compositions For Regulating Protein-Protein Interactions
The invention relates to methods and compositions of WW-domains as phosphoserine and phosphothreonine binding modules. The WW-domain containing polypeptides of the invention can be used, for example, to regulate cell growth; to treat neurodegenerative diseases; to screen for substances that modulated interactions between WW-domain containing polypeptides and phosphorylated ligands; as drug targeting vehicles; to direct protein degradation; and in the treatment of certain diseases or conditions characterized by aberrant WW-domain containing polypeptides or their ligands.
The present invention provides molecules including Pin2 and telomerase binding polypeptides, polynucleotides encoding such polypeptides, and antibodies specifically immunoreactive to said polypeptides. The invention also provides methods for screening agents which modulate the function or expression of said Pin2 and telomerase binding polypeptides. Methods are provided for disease diagnosis and treatment using said agents, said antibodies and oligonucleotides derived from the above polynucleotides.
Kun Lu - Newton MA, US Gerburg Wulf - Cambridge MA, US Xiao Zhou - Newton MA, US
International Classification:
G01N033/574
US Classification:
435007230
Abstract:
Methods for the use of Pin1 as a marker of abnormal cell growth are disclosed. In one embodiment, the method includes detecting a level of Pin1 to stage an abnormal cell growth, such as breast or prostate cancer. In another embodiment, the method includes evaluating the efficacy of a treatment of an abnormal cell growth, such as cancer, by monitoring the levels of Pin1. In another embodiment, the method includes evaluating the extent of metastasis of abnormal cell growth, such as cancer. The levels of Pin1 can be protein levels or nucleic acid levels.
Methods And Compositions For Regulating Protein-Protein Interactions
The invention relates to methods and compositions of WW-domains as phosphoserine and phosphothreonine binding modules. The WW-domain containing polypeptides of the invention can be used, for example, to regulate cell growth; to treat neurodegenerative diseases; to screen for substances that modulated interactions between WW-domain containing polypeptides and phosphorylated ligands; as drug targeting vehicles; to direct protein degradation; and in the treatment of certain diseases or conditions characterized by aberrant WW-domain containing polypeptides or their ligands.
Alzheimer's Disease Therapeutics Based On Pin-1 Catalyzed Conformational Changes In Phosphorylated Amyloid Precursor Protein
The present invention is directed to inhibiting amyloidogenic processing of amyloid precursor protein, and/or inhibiting production of amyloid beta peptides. These methods can involve accelerating cis/trans isomerization of amyloid precursor protein at a phosphorylated serine/threonine-proline motif and/or contacting a cell with a compound that mimics the cis conformation of a phosphorylated serine/threonine-proline motif of an amyloid precursor protein. The present invention also relates to treating and/or preventing in a subject a degenerative neurological disease characterized by amyloidogenic processing of amyloid precursor protein and/or overproduction of amyloid beta peptide. This method involves administering an agent that accelerates cis/trans isomerization of amyloid precursor protein at a phosphorylated serine/threonine-proline motif and/or inhibits production of amyloid β peptides. Methods of screening for therapeutic agents effective in treating and/or preventing such diseases, methods of screening for biological molecules involved in the amyloidogenic pathway, and compounds that mimic the cis conformation of a phosphorylated serine/threonine-proline motif of an amyloid precursor protein are also disclosed.
Hello! My name is Xiao Zhou and I graduated a year ago from Tulane University with a Bachelor's degree double majoring in biomedical engineering and philosophy. Currently, I'm working toward m...